

**TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED**

(Company Registration No. 91120000103100784F)

(Incorporated in People's Republic of China)

---

**Resolutions Passed at the 3<sup>rd</sup> Board Meeting for FY2018**

---

***The board of directors (the "Board") of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited collectively and individually accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.***

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the "**Company**") had on 26 April 2018 duly convened its 3<sup>rd</sup> Board Meeting for the financial year ending 31 December 2018 ("**FY2018**"). The following resolutions were discussed and passed by the 6 directors out of the full board of 7 directors, with Ms. Wang Lei being absent.

The said meeting was convened in compliance with the applicable Companies Law, Securities Law and the Articles of Association of the Company, and the following resolutions were passed:

1. That, the full text and summary of the first quarter financial statement for FY2018, prepared in accordance with the accounting standards of the People's Republic of China (the "**PRC**"), and the first quarter financial statement for FY2018, prepared in accordance with the International Financial Reporting Standards, be approved.

To the best knowledge of the Directors and the management of the Company, there are no other information that will cause the contents of the aforesaid financial statements to be false or misleading.

2. That the amendments to the *Rules of the General Manager's Executive Meeting* be approved.

By order of the Board

Jiao Yan

27 April 2018